3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Myeloid, Acute
101
Leukemia
98
Precursor Cell Lymphoblastic Leukemia-Lymphoma
95
Myelodysplastic Syndromes
83
Leukemia, Lymphocytic, Chronic, B-Cell
78
Lymphoma, Non-Hodgkin
76
Multiple Myeloma
67
Hodgkin Disease
67
Lymphoma, Mantle-Cell
63
Lymphoma
62
Lymphoma, Large B-Cell, Diffuse
60
Lymphoma, Follicular
59
Leukemia, Myeloid, Chronic-Phase
57
Lymphoma, B-Cell, Marginal Zone
53
Burkitt Lymphoma
53
Lymphoma, Large-Cell, Immunoblastic
49
Leukemia, Myeloid, Accelerated Phase
48
Congenital Abnormalities
48
Myeloproliferative Disorders
46
Leukemia, Myelomonocytic, Chronic
43
Anemia, Refractory, with Excess of Blasts
41
Graft vs Host Disease
37
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
36
Blast Crisis
33
Recurrence
32
Dendritic Cell Sarcoma, Interdigitating
32
Primary Myelofibrosis
27
Lymphoma, T-Cell, Cutaneous
27
Neoplasms, Plasma Cell
26
Waldenstrom Macroglobulinemia
25
Interventions
Standard of Care
3
Educational Status
2
vilanterol
1
tocilizumab
1
perflutren
1
X-Rays
1
Tiotropium Bromide
1
Therapeutics
1
Telemedicine
1
Tablets
1
Surgical Procedures, Operative
1
Sulfur Hexafluoride
1
Specimen Handling
1
Singing
1
Salmeterol Xinafoate
1
Rehabilitation
1
Pulmonary Surgical Procedures
1
Prednisolone
1
Practice Guidelines as Topic
1
Pharmacists
1
Methods
1
Massage
1
Magnesium Sulfate
1
Lysine Acetyltransferase 5
1
Immunoglobulin G
1
Iloprost
1
Hypnosis
1
Hematologic Tests
1
Geritol
1
General Practitioners
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pulmonary Disease, Chronic Obstructive
×
Cyclosporine
×
Clear all
NCT06892756
2025-09-09
DDI2
Chiesi Farmaceutici S.p.A.
Phase 1
Completed
30 enrolled